Literature DB >> 17928341

Preserved central memory and activated effector memory CD4+ T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study.

Simon J Potter1, Christine Lacabaratz, Olivier Lambotte, Santiago Perez-Patrigeon, Benoît Vingert, Martine Sinet, Jean-Hervé Colle, Alejandra Urrutia, Daniel Scott-Algara, Faroudy Boufassa, Jean-François Delfraissy, Jacques Thèze, Alain Venet, Lisa A Chakrabarti.   

Abstract

Human immunodeficiency virus (HIV) controllers are rare individuals who spontaneously control HIV type 1 replication for 10 years or more in the absence of antiretroviral treatment. In the present study, HIV controllers (n = 11) maintained potent HIV-specific CD4 responses in spite of very low antigenic loads. Their CD4+ central memory T (T(CM)) cells were characterized by near-normal numbers and preserved interleukin-2 (IL-2) secretion in response to HIV antigens and uniformly high expression of the survival receptor IL-7 receptor alpha (IL-7Ralpha). Controllers expressed CCR7 at higher levels than uninfected controls, suggesting differences in T(CM)-cell homing patterns. CD4+ effector memory T (T(EM))-cell responses were polyfunctional in HIV controllers, while IL-2 secretion was lost in viremic patients. Cytokine production was three times higher in controllers than in treated patients with undetectable viral loads, suggesting an intrinsically more efficient response in the former group. The total CD4+ T(EM)-cell pool underwent immune activation in controllers, as indicated by increased HLA-DR expression, decreased IL-7Ralpha expression, a bias towards gamma interferon production upon polyclonal stimulation, and increased macrophage inflammatory protein 1beta secretion associated with chronic CCR5 down-regulation. Thus, HIV controllers showed a preserved CD4+ T(CM)-cell compartment and signs of potent functional activation in the CD4+ T(EM)-cell compartment. While controllers did not show the generalized immune activation pattern associated with disease progression, they had signs of immune activation restricted to the effector compartment. These findings suggest the induction of an efficient, nondetrimental type of immune activation in patients who spontaneously control HIV.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17928341      PMCID: PMC2168869          DOI: 10.1128/JVI.01401-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  61 in total

1.  HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors.

Authors:  Stephen A Migueles; Alisha C Laborico; W Lesley Shupert; M Shirin Sabbaghian; Ronald Rabin; Claire W Hallahan; Debbie Van Baarle; Stefan Kostense; Frank Miedema; Mary McLaughlin; Linda Ehler; Julia Metcalf; Shuying Liu; Mark Connors
Journal:  Nat Immunol       Date:  2002-10-07       Impact factor: 25.606

2.  Replication-competent HIV strains infect HIV controllers despite undetectable viremia (ANRS EP36 study).

Authors:  Aurelia Lamine; Anne Caumont-Sarcos; Marie-Laure Chaix; Asier Saez-Cirion; Christine Rouzioux; Jean-François Delfraissy; Gianfranco Pancino; Olivier Lambotte
Journal:  AIDS       Date:  2007-05-11       Impact factor: 4.177

3.  HIV preferentially infects HIV-specific CD4+ T cells.

Authors:  Daniel C Douek; Jason M Brenchley; Michael R Betts; David R Ambrozak; Brenna J Hill; Yukari Okamoto; Joseph P Casazza; Janaki Kuruppu; Kevin Kunstman; Steven Wolinsky; Zvi Grossman; Mark Dybul; Annette Oxenius; David A Price; Mark Connors; Richard A Koup
Journal:  Nature       Date:  2002-05-02       Impact factor: 49.962

4.  Presence of HIV-1 Gag-specific IFN-gamma+IL-2+ and CD28+IL-2+ CD4 T cell responses is associated with nonprogression in HIV-1 infection.

Authors:  Mark J Boaz; Anele Waters; Shahed Murad; Philippa J Easterbrook; Annapurna Vyakarnam
Journal:  J Immunol       Date:  2002-12-01       Impact factor: 5.422

Review 5.  The impact of CCR7 and CXCR5 on lymphoid organ development and systemic immunity.

Authors:  Gerd Müller; Uta E Höpken; Martin Lipp
Journal:  Immunol Rev       Date:  2003-10       Impact factor: 12.988

6.  Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy.

Authors:  Alexandre Harari; Stéphanie Petitpierre; Florence Vallelian; Giuseppe Pantaleo
Journal:  Blood       Date:  2003-09-04       Impact factor: 22.113

7.  Fully differentiated HIV-1 specific CD8+ T effector cells are more frequently detectable in controlled than in progressive HIV-1 infection.

Authors:  Marylyn M Addo; Rika Draenert; Almas Rathod; Cori L Verrill; Benjamin T Davis; Rajesh T Gandhi; Gregory K Robbins; Nesli O Basgoz; David R Stone; Daniel E Cohen; Mary N Johnston; Theresa Flynn; Alysse G Wurcel; Eric S Rosenberg; Marcus Altfeld; Bruce D Walker
Journal:  PLoS One       Date:  2007-03-28       Impact factor: 3.240

8.  Interleukin-2 enhances CD4+ T cell memory by promoting the generation of IL-7R alpha-expressing cells.

Authors:  Hans Dooms; Kristen Wolslegel; Patricia Lin; Abul K Abbas
Journal:  J Exp Med       Date:  2007-02-20       Impact factor: 14.307

9.  HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity.

Authors:  Souheil-Antoine Younes; Bader Yassine-Diab; Alain R Dumont; Mohamed-Rachid Boulassel; Zvi Grossman; Jean-Pierre Routy; Rafick-Pierre Sekaly
Journal:  J Exp Med       Date:  2003-12-15       Impact factor: 14.307

10.  Progressive CD4+ central memory T cell decline results in CD4+ effector memory insufficiency and overt disease in chronic SIV infection.

Authors:  Afam Okoye; Martin Meier-Schellersheim; Jason M Brenchley; Shoko I Hagen; Joshua M Walker; Mukta Rohankhedkar; Richard Lum; John B Edgar; Shannon L Planer; Alfred Legasse; Andrew W Sylwester; Michael Piatak; Jeffrey D Lifson; Vernon C Maino; Donald L Sodora; Daniel C Douek; Michael K Axthelm; Zvi Grossman; Louis J Picker
Journal:  J Exp Med       Date:  2007-08-27       Impact factor: 14.307

View more
  83 in total

1.  Broadly-specific cytotoxic T cells targeting multiple HIV antigens are expanded from HIV+ patients: implications for immunotherapy.

Authors:  Sharon Lam; Julia Sung; Conrad Cruz; Paul Castillo-Caro; Minhtran Ngo; Carolina Garrido; Joann Kuruc; Nancie Archin; Cliona Rooney; David Margolis; Catherine Bollard
Journal:  Mol Ther       Date:  2014-11-04       Impact factor: 11.454

2.  HIV controllers with HLA-DRB1*13 and HLA-DQB1*06 alleles have strong, polyfunctional mucosal CD4+ T-cell responses.

Authors:  April L Ferre; Peter W Hunt; Delandy H McConnell; Megan M Morris; Juan C Garcia; Richard B Pollard; Hal F Yee; Jeffrey N Martin; Steven G Deeks; Barbara L Shacklett
Journal:  J Virol       Date:  2010-08-18       Impact factor: 5.103

3.  Stable Phenotypic Changes of the Host T Cells Are Essential to the Long-Term Stability of Latent HIV-1 Infection.

Authors:  Lillian Seu; Steffanie Sabbaj; Alexandra Duverger; Frederic Wagner; Joshua C Anderson; Elizabeth Davies; Frank Wolschendorf; Christopher D Willey; Michael S Saag; Paul Goepfert; Olaf Kutsch
Journal:  J Virol       Date:  2015-04-15       Impact factor: 5.103

4.  Differential Gag-specific polyfunctional T cell maturation patterns in HIV-1 elite controllers.

Authors:  Sara Ferrando-Martínez; Joseph P Casazza; Manuel Leal; Kawthar Machmach; Ma Ángeles Muñoz-Fernández; Pompeyo Viciana; Richard A Koup; Ezequiel Ruiz-Mateos
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

5.  Plasmacytoid dendritic cells reduce HIV production in elite controllers.

Authors:  K Machmach; M Leal; C Gras; P Viciana; M Genebat; E Franco; F Boufassa; O Lambotte; J P Herbeuval; E Ruiz-Mateos
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

6.  Immunogenicity and safety of a booster dose of an investigational adjuvanted polyprotein HIV-1 vaccine in healthy adults and effect of administration of chloroquine.

Authors:  Geert Leroux-Roels; Patricia Bourguignon; Julie Willekens; Michel Janssens; Frédéric Clement; Arnaud M Didierlaurent; Laurence Fissette; François Roman; Dominique Boutriau
Journal:  Clin Vaccine Immunol       Date:  2014-01-03

7.  Effective B cell activation in vitro during viremic HIV-1 infection with surrogate T cell stimulation.

Authors:  Lindsay K Nicholson; Harsh Pratap; Elisabeth Bowers; Elise Gunzburger; Srinivasa R Bandi; Edward M Gardner; Brent E Palmer; Timothy Wright; John Kittelson; Edward N Janoff
Journal:  Immunobiology       Date:  2018-09-07       Impact factor: 3.144

8.  Low antigen-specific CD4 T-cell immune responses despite normal absolute CD4 counts after long-term antiretroviral therapy an African cohort.

Authors:  Rose Nabatanzi; Lois Bayigga; Isaac Ssinabulya; Agnes Kiragga; Andrew Kambugu; Joseph Olobo; Moses Joloba; Moses R Kamya; Harriet Mayanja-Kizza; Damalie Nakanjako
Journal:  Immunol Lett       Date:  2014-09-26       Impact factor: 3.685

9.  Targeting concatenated HIV antigens to human CD40 expands a broad repertoire of multifunctional CD4+ and CD8+ T cells.

Authors:  Anne-Laure Flamar; Yaming Xue; Sandra M Zurawski; Monica Montes; Bryan King; Louis Sloan; SangKon Oh; Jacques Banchereau; Yves Levy; Gerard Zurawski
Journal:  AIDS       Date:  2013-08-24       Impact factor: 4.177

10.  HIV controller CD4+ T cells respond to minimal amounts of Gag antigen due to high TCR avidity.

Authors:  Benoît Vingert; Santiago Perez-Patrigeon; Patricia Jeannin; Olivier Lambotte; Faroudy Boufassa; Fabrice Lemaître; William W Kwok; Ioannis Theodorou; Jean-François Delfraissy; Jacques Thèze; Lisa A Chakrabarti
Journal:  PLoS Pathog       Date:  2010-02-26       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.